I-Mab is a clinical stage biopharmaceutical company. It engages in discovering, developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zhang Zang on June 30, 2016 and is headquartered in Pudong, China. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$6.04  -0.10 (-1.63%)
As of 02/03/2023 14:25:34 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  China
Country of incorporation:  
IPO date:  01/17/2020
Outstanding shares:  83,098,842
Average volume:  822,387
Market cap:   $524,353,693
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      BKRRKY7
Valuation   (See tab for details)
PE ratio:   0.77
PB ratio:   0.11
PS ratio:   0.33
Return on equity:   2.67%
Net income %:   7.78%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy